NEW: Premarket Now Starts at 4AM!

We’re excited to announce the extension of premarket and aftermarket hours! Our members now have access to quotes daily from 4:00 AM to 8:00 PM ET — offering greater flexibility and deeper insights into market trends beyond regular trading hours.

Upgrade to FINVIZ*Elite to access premarket quotes »

ACTU

Actuate Therapeutics Inc

Apr 25 • 04:00PM ET

8.95

Dollar change -0.09
Percentage change -1.00	%

Healthcare • Biotechnology • USA • NASD

Peers: JNJ LLY MRNA PFE MRK REGN BNTX GILD NVAX VIR

| Held by: VXF IWC VTI

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-1.41	Insider Own	69.92%	Shs Outstand	19.53M	Perf Week	11.87%
Market Cap	174.79M	Forward P/E	-	EPS next Y	-1.37	Insider Trans	0.00%	Shs Float	5.88M	Perf Month	11.87%
Income	-27.29M	PEG	-	EPS next Q	-0.30	Inst Own	1.14%	Short Float	2.22%	Perf Quarter	-11.47%
Sales	0.00M	P/S	-	EPS this Y	64.93%	Inst Trans	1.90%	Short Ratio	3.49	Perf Half Y	16.99%
Book/sh	0.01	P/B	1679.17	EPS next Y	-19.83%	ROA	-	Short Interest	0.13M	Perf Year	-
Cash/sh	0.44	P/C	20.23	EPS next 5Y	20.96%	ROE	-	52W Range	5.51 - 11.73	Perf YTD	12.44%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-5358.71%	52W High	-23.70%	Beta	-
Dividend TTM	-	Quick Ratio	1.05	Sales past 5Y	0.00%	Gross Margin	-	52W Low	62.43%	ATR (14)	0.70
Dividend Ex-Date	-	Current Ratio	1.05	EPS Y/Y TTM	-	Oper. Margin	-	RSI (14)	65.19	Volatility	8.99% 10.59%
Employees	10	Debt/Eq	4.00	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	20.33
Option/Short	No / Yes	LT Debt/Eq	4.00	EPS Q/Q	-1.69%	Payout	-	Rel Volume	3.48	Prev Close	9.04
Sales Surprise	-	EPS Surprise	-13.79%	Sales Q/Q	-	Earnings	Feb 26	Avg Volume	37.32K	Price	8.95
SMA20	15.94%	SMA50	19.68%	SMA200	11.49%	Trades		Volume	129,997	Change	-1.00%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-22-25	Initiated	Craig Hallum	Buy	$21
Mar-17-25	Initiated	H.C. Wainwright	Buy	$20

Apr-23-25 10:24AM	Actuate to Present Elraglusib Phase 2 Topline Data at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting (GlobeNewswire) +5.63%
Apr-17-25 08:00AM	Actuate to Present Promising Data on Elraglusib in Advanced Salivary Gland Carcinoma at the AACR Annual Meeting 2025 (GlobeNewswire)
Mar-27-25 04:01PM	Lantern Pharma Provides Business Updates and Fourth Quarter & Year-End 2024 Financial Results (Business Wire) -5.25%
Mar-26-25 09:15AM	Actuate Therapeutics: Looking To Make An Impact In Pancreatic Cancer (SeekingAlpha)
Feb-25-25 08:00AM	Actuate Announces Completion of Enrollment in a Phase 2 Trial of Elraglusib in Combination with FOLFIRINOX and Losartan in Patients with Previously Untreated Metastatic Pancreatic Cancer (GlobeNewswire)
08:00AM	Loading…
Feb-06-25 08:00AM	Actuate Therapeutics to Participate in Upcoming Investor Conferences in February (GlobeNewswire) -6.56%
Jan-07-25 08:00AM	Actuate Therapeutics Receives EMA Orphan Medicinal Product Designation for Elraglusib for the Treatment of Pancreatic Cancer (GlobeNewswire)
Dec-17-24 08:28AM	Actuate Therapeutics Announces Positive Interim Phase 2 Data of Elraglusib in First Line Treatment of Metastatic Pancreatic Cancer (GlobeNewswire) -11.85%
Nov-26-24 08:00AM	Actuate Therapeutics to be Added to Russell 2000 Index (GlobeNewswire)
Nov-12-24 08:00AM	Actuate Announces FDA Rare Pediatric Disease Designation Granted to Elraglusib for Treatment of Ewing Sarcoma (GlobeNewswire)
Oct-29-24 06:39PM	Actuate to Participate in Lantern's Pharma Webinar on AI-Driven Drug Development (GlobeNewswire)
Sep-23-24 08:00AM	Actuate Announces Scientific Reports Publication on Elraglusib's Novel Immunomodulatory Mechanism of Action as a GSK-3 Inhibitor (GlobeNewswire) -8.89%
Sep-16-24 08:00AM	Actuate Announces Upcoming Presentation on Initial Data on Elraglusib in Combination with FOLFIRINOX at the AACR Special Conference on Advances in Pancreatic Cancer Research (GlobeNewswire)
Sep-11-24 08:00AM	Actuate Receives FDA Orphan Drug Designation for Elraglusib for Treatment of Soft Tissue Sarcomas (GlobeNewswire)
Sep-09-24 08:00AM	Actuate Therapeutics Obtains Complete Responses and Provides Update on Clinical Trial of Elraglusib for the Treatment of Relapsed/Refractory Ewing Sarcoma (GlobeNewswire)
09:10AM	Loading…
Sep-05-24 09:10AM	Actuate to Present at the H.C. Wainwright 26th Annual Global Investment Conference (GlobeNewswire)
Aug-20-24 09:00AM	Actuate Therapeutics to Ring the Nasdaq Opening Bell on Friday, August 23, 2024 (GlobeNewswire)
Aug-14-24 04:05PM	Actuate Therapeutics Announces Closing of Initial Public Offering (GlobeNewswire) +6.27%
Aug-12-24 08:27PM	Actuate Therapeutics Announces Pricing of Initial Public Offering (GlobeNewswire)
May-28-24 07:00AM	Actuate Therapeutics Files Registration Statement for Initial Public Offering (GlobeNewswire)

Actuate Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in developing therapeutics which target cancers and neurodegenerative diseases. It offers treatment for cancer and inflammatory diseases. It focuses on developing elraglusib. The company was founded by Andrew P. Mazar on January 16, 2015 and is headquartered in Fort Worth, TX.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
THOMSON TODD S	16.4% Owner	Aug 14 '24	Sale	8.00	18,750	150,000	1,184,795	Aug 16 09:12 PM
Bios Equity COF, LP	Director	Aug 14 '24	Buy	8.00	500,000	4,000,000	1,259,427	Aug 14 08:54 PM
Bios Equity COF, LP	Director	Aug 14 '24	Sale	9.00	24,999	224,991	131,248	Aug 14 08:54 PM
Fletcher Aaron G.L.	Director	Aug 14 '24	Buy	8.00	500,000	4,000,000	1,259,427	Aug 14 08:49 PM
Fletcher Aaron G.L.	Director	Aug 14 '24	Sale	9.00	24,999	224,991	131,248	Aug 14 08:49 PM
Kreis Leslie W.	10% Owner	Aug 14 '24	Buy	8.00	500,000	4,000,000	1,259,427	Aug 14 08:44 PM
Kreis Leslie W.	10% Owner	Aug 14 '24	Sale	9.00	24,999	224,991	131,248	Aug 14 08:44 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ACTU

Actuate Therapeutics Inc

Upgrade your FINVIZ experience